Taiko Pharmaceutical Co.,Ltd.
TSE:4574.T
378 (JPY) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 5,040 | 10,720 | 17,683.989 | 14,936.165 | 10,377.646 | 9,438.366 | 8,284.887 | 8,295.288 | 9,237.774 | 9,868.287 | 7,415.743 | 6,690.812 | 4,470.424 | 8,733.433 | 6,091.323 | 5,542.12 |
| Cost of Revenue
| 3,961 | 7,973 | 5,263.129 | 4,357.793 | 3,215.812 | 2,885.892 | 2,713.994 | 2,556.255 | 2,354.776 | 2,683.659 | 2,407.842 | 2,201.473 | 1,584.215 | 2,437.648 | 1,644.275 | 1,588.879 |
| Gross Profit
| 1,079 | 2,747 | 12,420.86 | 10,578.372 | 7,161.834 | 6,552.474 | 5,570.893 | 5,739.033 | 6,882.998 | 7,184.628 | 5,007.901 | 4,489.339 | 2,886.209 | 6,295.785 | 4,447.048 | 3,953.241 |
| Gross Profit Ratio
| 0.214 | 0.256 | 0.702 | 0.708 | 0.69 | 0.694 | 0.672 | 0.692 | 0.745 | 0.728 | 0.675 | 0.671 | 0.646 | 0.721 | 0.73 | 0.713 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 410 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 3,189 | 4,695.423 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 1,942 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 0 | 0 | 0 | 0 | 5,131 | 4,695.423 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Expenses
| 4,157 | 7,694 | 6,769.871 | -282.124 | -188.136 | -249.06 | -182.427 | -22.862 | 21.241 | 21.905 | 14.489 | 31.818 | 88.45 | 22.265 | -10.456 | 56.748 |
| Operating Expenses
| 4,157 | 7,694 | 6,769.871 | 6,753.792 | 5,131.907 | 4,695.423 | 4,025.488 | 4,391.335 | 4,323.776 | 4,593.84 | 3,886.903 | 3,974.335 | 4,128.775 | 3,806.568 | 3,552.676 | 3,281.096 |
| Operating Income
| -3,079 | -4,948 | 5,650.987 | 3,824.578 | 2,029.926 | 1,857.05 | 1,545.405 | 1,347.696 | 2,559.221 | 2,590.787 | 1,120.997 | 515.003 | -1,242.565 | 2,489.216 | 894.371 | 672.144 |
| Operating Income Ratio
| -0.611 | -0.462 | 0.32 | 0.256 | 0.196 | 0.197 | 0.187 | 0.162 | 0.277 | 0.263 | 0.151 | 0.077 | -0.278 | 0.285 | 0.147 | 0.121 |
| Total Other Income Expenses Net
| -1,790 | -3,939 | -276.717 | -320.253 | -45 | -304.305 | -54.374 | -156.171 | 199.397 | -37.115 | -20.436 | -100.452 | -753.326 | 100.29 | -203.256 | -72.473 |
| Income Before Tax
| -4,869 | -8,887 | 5,374.27 | 3,504.326 | 1,985.983 | 1,552.745 | 1,491.031 | 1,191.525 | 2,758.618 | 2,553.672 | 1,100.561 | 414.551 | -1,995.892 | 2,589.506 | 691.115 | 599.671 |
| Income Before Tax Ratio
| -0.966 | -0.829 | 0.304 | 0.235 | 0.191 | 0.165 | 0.18 | 0.144 | 0.299 | 0.259 | 0.148 | 0.062 | -0.446 | 0.297 | 0.113 | 0.108 |
| Income Tax Expense
| 25 | 706 | 1,522.711 | 1,050.859 | 570.491 | 457.786 | 441.614 | 351.414 | 988.075 | 806.439 | 63.035 | -67.652 | 232.316 | 944.383 | 220.338 | 239.232 |
| Net Income
| -4,894 | -9,593 | 3,851.559 | 2,453.466 | 1,415.491 | 1,094.959 | 1,049.416 | 840.11 | 1,770.541 | 1,747.233 | 1,037.525 | 482.204 | -2,228.208 | 1,645.122 | 470.777 | 360.439 |
| Net Income Ratio
| -0.971 | -0.895 | 0.218 | 0.164 | 0.136 | 0.116 | 0.127 | 0.101 | 0.192 | 0.177 | 0.14 | 0.072 | -0.498 | 0.188 | 0.077 | 0.065 |
| EPS
| -112.24 | -220.48 | 89.18 | 57.57 | 33 | 25.8 | 25.48 | 21.74 | 46.31 | 45.31 | 27.1 | 12.41 | -57.85 | 42.99 | 36.91 | 37.84 |
| EPS Diluted
| -112.24 | -220.48 | 88.82 | 57.34 | 32.96 | 25.69 | 25.27 | 21.28 | 44.82 | 43.85 | 26.7 | 12.17 | -57.85 | 40.83 | 35.96 | 37.84 |
| EBITDA
| -3,750 | -5,568 | 5,923.512 | 4,066.036 | 2,389.895 | 2,325.866 | 1,906.888 | 1,660.838 | 2,857.539 | 2,979.445 | 1,482.6 | 918.23 | -197.738 | 2,643.847 | 1,223.525 | 833.255 |
| EBITDA Ratio
| -0.744 | -0.519 | 0.335 | 0.272 | 0.23 | 0.246 | 0.23 | 0.2 | 0.309 | 0.302 | 0.2 | 0.137 | -0.044 | 0.303 | 0.201 | 0.15 |